Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Eric L. Nuermberger"'
Autor:
Veronique De Jager, Nikhil Gupte, Silvia Nunes, Grace L. Barnes, Rob Christiaan van Wijk, Joni Mostert, Susan E. Dorman, Ahmed A. Abulfathi, Caryn M. Upton, Alan Faraj, Eric L. Nuermberger, Gyanu Lamichhane, Elin M. Svensson, Ulrika S. H. Simonsson, Andreas H. Diacon, Kelly E. Dooley
Publikováno v:
American Journal of Respiratory and Critical Care Medicine, 205, 1228-1235
American Journal of Respiratory and Critical Care Medicine, 205, 10, pp. 1228-1235
Am J Respir Crit Care Med
American Journal of Respiratory and Critical Care Medicine, 205, 10, pp. 1228-1235
Am J Respir Crit Care Med
RATIONALE: Carbapenems are recommended for treatment of drug-resistant tuberculosis. Optimal dosing remains uncertain. OBJECTIVES: To evaluate the 14-day bactericidal activity of meropenem, at different doses, with or without rifampin. METHODS: Indiv
Autor:
Rokeya Tasneen, Andrew Garcia, Paul J. Converse, Matthew D. Zimmerman, Veronique Dartois, Ekaterina Kurbatova, Andrew A. Vernon, Wendy Carr, Jason E. Stout, Kelly E. Dooley, Eric L. Nuermberger
Publikováno v:
Antimicrob Agents Chemother
A recent landmark trial showed a 4-month regimen of rifapentine, pyrazinamide, moxifloxacin and isoniazid (PZMH) to be non-inferior to the 6-month standard of care. Here, two murine models of tuberculosis were used to test whether novel regimens repl
Autor:
Christian Dide-Agossou, Allison A. Bauman, Michelle E. Ramey, Karen Rossmassler, Reem Al Mubarak, Samantha Pauly, Martin I. Voskuil, Maria Garcia-Cremades, Rada M. Savic, Payam Nahid, Camille M. Moore, Rokeya Tasneen, Eric L. Nuermberger, Gregory T. Robertson, Nicholas D. Walter
Publikováno v:
Antimicrobial agents and chemotherapy, vol 66, iss 4
Murine tuberculosis drug efficacy studies have historically monitored bacterial burden based on colony forming units of M. tuberculosis in lung homogenate. In an alternative approach, a recently described molecular pharmacodynamic marker called the R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43bdf80a9fca8cbb8ff52607c8490e5f
https://doi.org/10.1101/2021.12.21.473768
https://doi.org/10.1101/2021.12.21.473768
Autor:
Jacqueline P Ernest, Timothy R. Sterling, Rada M. Savic, Nan Zhang, Robert Belknap, Kendra K. Radtke, Nicole C. Ammerman, Rosanna Boyd, Eric L. Nuermberger
Publikováno v:
Antimicrobial agents and chemotherapy, vol 65, iss 12
Antimicrobial Agents and Chemotherapy, 65(12):e01705-21. American Society for Microbiology
Antimicrob Agents Chemother
Antimicrobial Agents and Chemotherapy, 65(12):e01705-21. American Society for Microbiology
Antimicrob Agents Chemother
Rifapentine has facilitated treatment shortening for latent tuberculosis infection (LTBI) in combination with isoniazid once weekly for 3 months (3HP) or daily for 1 month (1HP). Our objective was to determine the optimal rifapentine dose for a 6-wee
Autor:
Deepak V. Almeida, Jeongjun Kim, Sandeep Tyagi, Eric L. Nuermberger, Paul J. Converse, Till F. Omansen, Rokeya Tasneen
Publikováno v:
Antimicrobial Agents and Chemotherapy, 64(6):e00259-20. AMER SOC MICROBIOLOGY
Antimicrob Agents Chemother
Antimicrob Agents Chemother
Telacebec (Q203) is a new antitubercular drug with extremely potent activity against Mycobacterium ulcerans. Here, we explored the treatment-shortening potential of Q203 alone or in combination with rifampin (RIF) in a mouse footpad infection model.
Autor:
Jotam G. Pasipanodya, Shashikant Srivastava, Tawanda Gumbo, Eric L. Nuermberger, Soumya Swaminathan, A K Hemanth Kumar, Devyani Deshpande, Geetha Ramachandran
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Background. The role of drug concentrations in clinical outcomes in children with tuberculosis is unclear. Target concentrations for dose optimization are unknown. Methods. Plasma drug concentrations measured in Indian children with tuberculosis were
Autor:
Devyani Deshpande, Eric L. Nuermberger, Tania A Thomas, Soumya Swaminathan, Shashikant Srivastava, Tawanda Gumbo, Jotam G. Pasipanodya
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Children with tuberculosis are treated with drug regimens copied from adults despite significant differences in antibiotic pharmacokinetics, pathology, and the microbial burden between childhood and adult tuberculosis. We sought to develop a new and
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Buruli ulcer is treatable with antibiotics. An 8-week course of rifampin (RIF) and either streptomycin (STR) or clarithromycin (CLR) cures over 90% of patients. However, STR requires injections and may be toxic, and CLR shares an adverse drug-drug in
Autor:
Jacques H. Grosset, Richard E. Chaisson, Sanjay K. Jain, Eric L. Nuermberger, Vikram Saini, Rokeya Tasneen, Nicole C. Ammerman, Yong Seok Chang
Publikováno v:
Antimicrobial agents and chemotherapy. 63(6)
Clofazimine and high-dose rifapentine have each separately been associated with treatment-shortening activity when incorporated into tuberculosis (TB) treatment regimens. We hypothesized that both modifications, i.e., the addition of clofazimine and
Publikováno v:
Antimicrobial Agents and Chemotherapy. 60:1091-1096
Pyrazinamide (PZA) is a key sterilizing drug in first-line tuberculosis (TB) regimens and exerts its activity entirely during the first 2 months in human infections. We recently described the reduced activity of PZA in C3HeB/FeJ mice with large caseo